Table 1 Baseline characteristics.
Characteristic | Number of patients (%) |
|---|---|
Age, years | |
Median (range) | 58 (41–71) |
Sex | |
Female | 18 (100) |
Race | |
White | 15 (83) |
Black | 1 (6) |
Other | 2 (11) |
ECOG PS at baseline | |
0 | 18 (100) |
Sites of disease | |
Lung pleural | 6 (33) |
Liver | 7 (39) |
Bone | 8 (44) |
Breast/chest wall | 7 (39) |
Lymph node | 11 (61) |
Soft tissue | 3 (17) |
Adjuvant or neoadjuvant treatment | |
Adjuvant or neoadjuvant hormonal therapy | 1 (6) |
Adjuvant or or neoadjuvant anthracycline | 12 (67) |
Adjuvant or neoadjuvant taxane | 12 (67) |
Lines of chemotherapy for metastasis or recurrence | |
Median (range) | 1 (0–3) |
0 | 5 (28) |
1 | 6 (33) |
2 | 5 (28) |
3 | 2 (11) |
Prior metastatic chemotherapy | |
Anthracycline | 4 (22) |
Taxane | 5 (28) |
Platinum | 11 (61) |
Capecitabine | 2 (11) |
Eribulin | 2 (11) |
Other chemotherapy | 6 (33) |
ER, PR, and HER2 status at study entry | |
ER and/or PR-positive (≤10%), HER2-negative | 2 (11) |
ER and PR negative, HER2-negative | 16 (89) |
PD-L1-positive cellsa | 1 (7) |
TILs in metastatic samplesb | 3 (27) |
